E6AP is required for replicative and oncogene-induced senescence in mouse embryo fibroblasts

Oncogene

Volumn 31, Issue 17, 2012, Pages 2199-2209

  Levav Cohen, Y ^a   Wolyniec, K ^b   Alsheich Bartok, O ^a   Chan, A L ^b   Woods, S J ^b   Jiang, Y H ^c   Haupt, S ^b   Haupt, Y ^b  

^a HEBREW UNIVERSITY   (Israel)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cellular senescence; E6AP; p53; Ras; stress

Indexed keywords

PROTEIN E6AP; PROTEIN P53; RAS PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL AGING; CELL DIVISION; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; EMBRYO CELL; ENZYME ACTIVITY; FEMALE; FIBROBLAST; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; CELL AGING; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EMBRYO, MAMMALIAN; FIBROBLASTS; MICE; MICE, KNOCKOUT; MICE, NUDE; STRESS, PHYSIOLOGICAL; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

MUS;

EID: 84860274471     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.402     Document Type: Article

References (56)

1. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE. et al. (2002). Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419: 162-167.
2. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N. et al. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633-637.
3. Beaudenon S, Huibregtse JM. (2008). HPV E6, E6AP and cervical cancer. BMC Biochem 9(Suppl 1): S4.
4. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA. et al. (1997). Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91: 25-34.
5. Campisi J. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120: 513-522.
6. Campisi J, d'Adda di Fagagna F. (2007). Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740.
7. Ciechanover A. (2006). The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 66: S7-19.
8. Collado M, Serrano M. (2006). The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6: 472-476.
9. Collado M, Serrano M. (2010). Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10: 51-57.
10. Dannenberg JH, van Rossum A, Schuijff Lte Riele H. (2000). Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev 14: 3051-3064.
11. Di Micco R, Cicalese A, Fumagalli M, Dobreva M, Verrecchia A, Pelicci PG. et al. (2008). DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization. Cell Cycle 7: 3601-3606.
12. Di Micco R, Fumagalli M, d'Adda di Fagagna F. (2007). Breaking news: high-speed race ends in arrest-how oncogenes induce senescence. Trends Cell Biol 17: 529-536.
13. Dimri GP. (2005). What has senescence got to do with cancer? Cancer Cell 7: 505-512.
14. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C. et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367.
15. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ. et al. (2002). Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 22: 3497-3508.
16. Frank KM, Sharpless NE, Gao Y, Sekiguchi JM, Ferguson DO, Zhu C. et al. (2000). DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell 5: 993-1002.
17. Gil J, Peters G. (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7: 667-677.
18. Halazonetis TD, Gorgoulis VG, Bartek J. (2008). An oncogeneinduced DNA damage model for cancer development. Science 319: 1352-1355.
19. Harvey M, McArthur MJ, Montgomery Jr CA, Bradley A, Donehower LA. (1993). Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 7: 938-943.
20. Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A. et al. (2009). Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res 69: 4818-4826.
21. Haupt Y, Barak Y, Oren M. (1996). Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 15: 1596-1606.
22. Howley PM. (2006). Warts, cancer and ubiquitylation: lessons from the papillomaviruses. Trans Am Clin Climatol Assoc 117: 113-126; discussion 126-117.
23. Huibregtse JM, Scheffner M, Howley PM. (1991). A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10: 4129-4135.
24. Jiang Y, Tsai TF, Bressler J, Beaudet AL. (1998a). Imprinting in Angelman and Prader-Willi syndromes. Curr Opin Genet Dev 8: 334-342.
25. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G. et al. (1998b). Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 21: 799-811.
26. Khan OY, Fu G, Ismail A, Srinivasan S, Cao X, Tu Y. et al. (2006 Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. Mol Endocrinol 20: 544-559.
27. Kortlever RM, Higgins PJ, Bernards R. (2006). Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8: 877-884.
28. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. (2010). The essence of senescence. Genes Dev 24: 2463-2479.
29. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB. et al. (2004). Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 36: 147-150.
30. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ, Oren M. (2000). Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci USA 97: 11250-11255.
31. Longworth MS, Laimins LA. (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68: 362-372.
32. Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T. et al. (2009). E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ 16: 1156-1166.
33. Maezawa Y, Yokote K, Sonezaki K, Fujimoto M, Kobayashi K, Kawamura H. et al. (2006). Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev 22: 313-322.
34. Matentzoglu K, Scheffner M. (2008). Ubiquitin ligase E6-AP and its role in human disease. Biochem Soc Trans 36: 797-801.
35. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS. et al. (1997). De novo truncating mutations in E6-AP ubiquitinprotein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 15: 74-77.
36. Mishra A, Godavarthi SK, Jana NR. (2009). UBE3A/E6-AP regulates cell proliferation by promoting proteasomal degradation of p27. Neurobiol Dis 36: 26-34.
37. Mishra A, Jana NR. (2008). Regulation of turnover of tumor suppressor p53 and cell growth by E6-AP, a ubiquitin protein ligase mutated in Angelman mental retardation syndrome. Cell Mol Life Sci 65: 656-666.
38. Mu XC, Higgins PJ. (1995). Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J Cell Physiol 165: 647-657.
39. Papazoglu C, Mills AA. (2007). p53: at the crossroad between cancer and ageing. J Pathol 211: 124-133.
40. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. (2003). Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5: 741-747.
41. Rodier F, Campisi J, Bhaumik D. (2007). Two faces of p53: aging and tumor suppression. Nucleic Acids Res 35: 7475-7484.
42. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR. et al. (2009). Persistent DNA damage signallingtriggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973-979.
43. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. (2003). Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424: 223-228.
44. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B. et al. (2000). Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev 14: 3037-3050.
45. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
46. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
47. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
48. Sherman MY, Gabai V, O'Callaghan C, Yaglom J. (2007). Molecular chaperones regulate p53 and suppress senescence programs. FEBS Lett 581: 3711-3715.
49. Sherr CJ, DePinho RA. (2000). Cellular senescence: mitotic clock or culture shock? Cell 102: 407-410.
50. Smith JR, Lincoln II DW. (1984). Aging of cells in culture. Int Rev Cytol 89: 151-177.
51. Talis AL, Huibregtse JM, Howley PM. (1998). The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)- positive and HPV-negative cells. J Biol Chem 273: 6439-6445.
52. Todaro GJ, Green H. (1963). Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 17: 299-313.
53. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L. et al. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
54. Wolyniec K, Wotton S, Kilbey A, Jenkins A, Terry A, Peters G. et al. (2009). RUNX1 and its fusion oncoprotein derivative, RUNX1- ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene 28: 2502-2512.
55. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. (2009). Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 219: 3-15.
56. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L. et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.